Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study-Reference-Cited by-同舟云学术

Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study

Published:2024-03 Issue:2 Volume:62 Page:284-290
ISSN:2212-5345
Container-title:Respiratory Investigation
language:en
Short-container-title:Respiratory Investigation

Author:

Morimoto Kozo^ORCID,Nonaka Mizu^ORCID,Yamazaki Yoshitaka,Nakagawa Taku^ORCID,Takasaki Jin,Tsuyuguchi Kazunari,Kitada Seigo,Jumadilova Zhanna,Yuen Dayton W.,Ciesielska Monika,Hasegawa Naoki^ORCID

Funder

Insmed Inc

Publisher

Elsevier BV

Reference39 articles.

1. Pulmonary disease by non-tuberculous mycobacteria - clinical management, unmet needs and future perspectives;Larsson;Expet Rev Respir Med,2017

2. High mortality in patients with Mycobacterium avium complex lung disease: a systematic review;Diel;BMC Infect Dis,2018

4. High-resolution computed tomography and health-related quality of life in Mycobacterium avium complex disease;Maekawa;Int J Tubercul Lung Dis,2013

5. Association between six-minute walk test parameters and the health-related quality of life in patients with pulmonary Mycobacterium avium complex disease;Yagi;BMC Pulm Med,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Amikacin Liposome Inhalation Suspension in the Real-World Management of Refractory Mycobacterium avium Complex Pulmonary Disease;Cureus;2024-03-21